Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02160535 : Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA
PhasePhase 3
AgesMin: 18 Years Max: 60 Years
Inclusion Criteria:

- Diagnosis of mild traumatic brain injury (mTBI) within the 12 months before screening

- Suffer at least fifteen total headache days per month

- Ability to speak and read English

Exclusion Criteria:

- Subject with hypersensitivity reactions or other intolerance to OnabotulinumtoxinA

- Previous use of OnabotulinumtoxinA for treatment of headache

- Any medications commonly used as headache preventives started less than 3 months
prior to enrollment

- Prior or current diagnosis of major psychiatric disorder or other central nervous
system disorder

- Less than 80% compliance (recorded for less than 24 days) in the 30 day screening
headache diary

- Subjects who are pregnant or trying to become pregnant within the timeframe of the
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557